Litcius/Paper detail

Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases

Marco Becilli, Markus Metzler, Claudia Bracaglia, Rebecca Nicolai, Tobias Krickau, Francesca Del Bufalo, Chiara Rosignoli, Emiliano Marasco, Nora Naumann-Bartsch, Virginia Messia, Pietro Merli, Daria Pagliara, Mattia Algeri, Aurelio Secinaro, Maria Giuseppina Cefalo, Francesca Diomedi Camassei, Valentina Bertaina, Matilde Sinibaldi, A Insalaco, Michael Aigner, Giovanna Leone, Giuseppina Li Pira, Monica Gunetti, Stefan Berg, Biagio De Angelis, Simon Völkl, Linda Hanssens, Fabian Müller, Andreas Mackensen, C. Quintarelli, Georg Schett, F De Benedetti, Franco Locatelli

2026Nature Medicine10 citationsDOI

Topics & Concepts

MedicineChimeric antigen receptorCytokine release syndromeDiscontinuationAdverse effectImmunologyT cellImmune systemRefractory (planetary science)Clinical trialInternal medicineDiseaseCell therapyCD19AntigenCD8Autoimmune diseaseTacrolimusCytokineB cellDrugHuman leukocyte antigenHematopoietic stem cell transplantationIntensive care medicineMarketing authorizationPharmacyCAR-T cell therapy researchCutaneous lymphoproliferative disorders researchInflammatory Myopathies and Dermatomyositis
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases | Litcius